Loading
A phase 1 trial of Tilatamig samrotecan, Osimertinib, Fluorouracil and Leucovorin in Head and neck squamous cell carcinoma, run by AstraZeneca, active and no longer recruiting.
First in Human Study of AZD9592 in Solid Tumors is a phase 1 interventional study registered as NCT05647122 by AstraZeneca, with 167 participants planned, started 2022-12-21 and due to reach its primary completion in 2028-08-03. Interventions recorded: AZD9592, Osimertinib, 5-Fluorouracil (5-FU), Leucovorin, Bevacizumab. Conditions recorded: Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms.
Linked to the drug Tilatamig samrotecan because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Leucovorin (folinic acid), Fluorouracil (5-FU), AstraZeneca and the tag pipeline.
Shares Osimertinib, AstraZeneca and the tag pipeline.
Shares Osimertinib, AstraZeneca and the tag pipeline.
Shares Leucovorin (folinic acid), Fluorouracil (5-FU) and the tag pipeline.
Shares Leucovorin (folinic acid), Fluorouracil (5-FU) and the tag pipeline.
Shares Osimertinib, AstraZeneca and the tag pipeline.
Shares Osimertinib, AstraZeneca and the tag pipeline.
Shares Leucovorin (folinic acid), Fluorouracil (5-FU) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/